Did you read the OP. The proposed AI use is equally a joke. This is another point showing he knows jack squat, i.e., FOS.
Again, it is hard to even get past the first example. The normal dose of Letrozole is 2.5 MG QD. [Recall the dose for later.] In his proposed use, the dose is ~25% TWICE PER WEEK for a total WEEKLY dose of 1.2 MG. If one took 2.5 MG QD, the total WEEKLY dose is 17.5 MG. Further, TE 500 MG/WEEK is being used.
Does anyone have an idea what happens under normal conditions? Would you believe that use of 2.5 MG QD will reduce E2 by ~50%.
Comparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase Inhibition This is ~15X the dose proposed.
And, that is UNDER eugonadal testosterone levels, NOT levels that will easily, very easily, approach 5,000-7,000 ng/dL. Or ~10 X normal testosterone levels. The E2 level with the proposed Letrozole use will still be elevated. They would be more elevated with TE 500 MG/WEEK.
T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman J-M. Comparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase Inhibition. Journal of Clinical Endocrinology & Metabolism 2005;90(10):5717-22. Comparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase Inhibition
Context: Aging in men is associated with a decline in serum testosterone (T) levels.Objective: Our objective was to assess whether decreased T in aging might result from increased estradiol (E2) negative feedback on gonadotropin secretion.
Design and Setting: We conducted a comparative intervention study (2004) in the Outpatient Endocrinology Clinic, Ghent University Hospital.
Participants: Participants included healthy young and elderly men (n = 10 vs. 10).Interventions: We used placebo and letrozole (2.5 mg/d) for 28 d, separated by 2 wk washout.
Main Outcome Measures: We assessed changes in serum levels of free E2, LH, and FSH, free T, SHBG, and gonadotropins response to an iv 2.5-mcg GnRH bolus.
Results: As assessed after 28 d of treatment, letrozole lowered E2 by 46% in the young men (P = 0.002) and 62% in the elderly men (P < 0.001). In both age groups, letrozole, but not placebo, significantly increased LH levels (339 and 323% in the young and the elderly, respectively) and T (146 and 99%, respectively) (P value of young vs. elderly was not significant). Under letrozole, peak LH response to GnRH was 152 and 52% increase from baseline in young and older men, respectively (P = 0.01).
Conclusions: Aromatase inhibition markedly increased basal LH and T levels and the LH response to GnRH in both young and elderly men. The observation of similar to greater LH responses in the young compared with the elderly does not support the hypothesis that increased restraining of LH secretion by endogenous estrogens is instrumental in age-related decline of Leydig cell function.
